Amarin Targets AstraZeneca In Suit Over Heart Medication

Law360, New York (March 4, 2014, 5:01 PM EST) -- Amarin Pharmaceuticals Ireland Ltd. on Tuesday hit AstraZeneca Pharmaceuticals LP with a lawsuit alleging that the company's heart medication Epanova will infringe on Amarin's patent for Vascepa, marking the second lawsuit within a week the company has filed to protect its rights to the triglyceride-reducing drug.

The lawsuit, filed in Delaware federal court, alleges that AstraZeneca and its subsidiary, Omthera Pharmaceuticals Inc., plan to begin marketing and selling Epanova following approval by the U.S. Food and Drug Administration. Doing so, however, will induce the direct infringement of at least...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.